Florida Facility Registrations

BIOXTEK QUALITY SYSTEM & REGULATORY DISCLOSURES

Compliance & Quality Assurance

BioXtek maintains transparent quality documentation, FDA establishment registration, state licenses, and verified product Instructions for Use (IFU) for healthcare partners.

Official Regulatory Records

Documented Quality & Facility Registrations

Access verified regulatory documentation for clinical onboarding and institutional tissue review.

Facility Registrations

Florida Manufacturing Site

BioXtek operates a Florida tissue processing facility subject to FDA Establishment Registration and state tissue bank licensing. FDA registration indicates establishment listing and does not constitute FDA endorsement or drug approval.

Instructions for Use (IFU)

Product-Specific Handling

Every BioXtek tissue patch ships with product-specific IFUs covering storage requirements, rehydration, handling instructions, and lot release documentation.

Sanoplast IFU CatalogRequest Current IFU →

AATB Accreditation Scope Disclosure

361 Placental Membrane Scope

BioXtek’s AATB accreditation covers its 361-product placental membrane processing scope at the time of accreditation. In compliance with strict regulatory standards:

AATB accreditation applies strictly to the verified 361 placental membrane product line (Sanoplast).
AATB accreditation does NOT extend to cosmetic products (BioXjel) or therapeutic drafts (BioXsomes / BioXcell).
BioXtek does not display "AATB Accredited" as a site-wide badge, product badge, or site footer badge.
Contact BioXtek Quality Assurance to request exact certificate dates, scope numbers, and verification records.
INTERNAL DRAFT SECTION · FOR KRISTEN’S REVIEW & REVISIONFlorida Statute SB 1768 Analysis

What Florida SB 1768 actually requires

The original marketing file included a discussion of Florida SB 1768. Below is the retained draft text, updated to distinguish stem-cell-specific requirements from exosome and cosmetic products:

01 — Stem Cell Statutory Notice: Florida law requires healthcare practitioners performing stem cell therapies to provide written statutory notice to patients prior to treatment stating that these therapies have not been approved by the US FDA.

02 — Scope Separation: SB 1768 applies specific requirements to stem cell practitioners. It does NOT state that exosome products are automatically authorized, nor does it equate state tissue banking laws with federal FDA approval.

03 — Post-Thaw Viability Testing: Post-thaw viability testing applies strictly to stem-cell cellular products where verified. It does not apply to acellular membranes or topical exosome cosmetics.

Request Official Documentation

Connect directly with BioXtek Quality & Regulatory Affairs to receive facility licenses, certificates of analysis, or IFUs.

Contact Quality & Compliance Team